newsfilter
← Latest News
Business Wire·

AN2 Therapeutics to Participate at Upcoming Investor Conferences

  • AN2 Therapeutics, Inc. announced that management will participate in three investor conferences in November 2026.
  • Eric Easom, Co-Founder, Chairman, President, & CEO, will present a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026.
  • Eric Easom will deliver a corporate overview at the Stifel 2026 Healthcare Conference on November 10, 2026.
  • Management will hold 1x1 meetings at the Jefferies London Conference on November 17, 2026.
  • Webcasts for the events will be available on the company website, with archived replays accessible for at least 30 days.
  • AN2 Therapeutics is a clinical stage biopharmaceutical company utilizing a boron chemistry platform to develop small molecule therapeutics for hematologic diseases, infectious diseases, & oncology.
  • The company expects three Phase 2 studies to be active in 2026, alongside two preclinical candidates & advanced research programs.